Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy

Molecular Therapy

Volumn 2, Issue 5, 2000, Pages 485-495

  Howe, John A ^a   Demers, G William ^a   Johnson, Duane E ^a   Neugebauer, Sarah E A ^a   Perry, Stuart T ^a   Vaillancourt, Mei Ting ^a   Faha, Barbara ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL LINE; CYTOPATHOGENIC EFFECT; DEFECTIVE VIRUS; DRUG SCREENING; EVALUATION; FEMALE; GENE THERAPY; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MUTATION; NEOPLASM; NUDE MOUSE; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DEFECTIVE VIRUSES; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034320414     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0206     Document Type: Article

References (60)

1. Seth, P., Katayose, Y., and Rakkar, A. N. S. (1999). Adenoviral vectors for cancer gene therapy. In Adenoviruses: Basic Biology to Gene Therapy (P. Seth, Ed.), Vol. 1, pp. 103-120. Landes, Austin, TX.
2. Vile, R. G., Russell, S. J., and Lemoine, N. R. (2000). Cancer gene therapy: Hard lessons and new courses. Gene Ther. 7: 2-8.
3. Bischoff, J. R., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 274: 373-376.
4. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559-2563.
5. Alemany, R., Lai, S., Lou, Y. C., Jan, H. Y., Fang, X., and Zhang, W. W. (1999). Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6: 21-25.
6. Hallenbeck, P. L., et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10: 1721-1733.
7. Shenk, T. (1996). Adenoviridae: The Viruses and Their Replication. In Fields Virology (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.), Vol. 2, pp. 2111-2148. Lippincott-Raven, Philadelphia, PA.
8. Howe, J. A., Mymryk, J. S., Egan, C., Branton, P. E., and Bayley, S. T. (1990). Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc. Natl. Acad. Sci. USA 87: 5883-5887.
9. Wang, H. G., Draetta, G., and Moran, E. (1991). E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol. Cell. Biol. 11: 4253-4265.
10. Howe, J. A., and Bayley, S. T. (1992). Effects of Ad5 E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology 186: 15-24.
11. Helin, K. (1998). Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8: 28-35.
12. Hamel, P. A., Gill, R. M., Phillips, R. A., and Gallie, B. L. (1992). Transcriptional repression of the E2-containing promoters EllaE, c-myc, and RB1 by the product of the RB1 gene. Mol. Cell. Biol. 12: 3431-3438.
13. Weintraub, S. J., Prater, C. A., and Dean, D. C. (1992). Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358: 259-261.
14. Luo, R. X., Postigo, A. A., and Dean, D. C. (1998). Rb interacts with histone deacetylase to repress transcription. Cell 192: 463-473.
15. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A., and Kouzarides, T. (2000). Regulation of E2F1 activity by acetylation. EMBO J. 19: 662-671.
16. Ait-Si-Ali, S., et al. (1998). Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396: 184-186.
17. White, E. (1998). Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8: 505-513.
18. Branton, P. E. (1999). Early gene expression. In Adenoviruses: Basic Biology to Gene Therapy (P. Seth, Ed.), Vol. 1, pp. 39-58. Landes, Austin, TX.
19. Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., and White, E. (1992). The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins [published erratum appears in Proc. Natl. Acad. Sci. USA 89: 9974]. Proc. Natl. Acad. Sci. USA 89: 7742-7746.
20. Boyd, J. M., et al. (1994). Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins [see comments] [published erratum appears in Cell 79:following 1120]. Cell 79: 341-351.
21. Subramanian, T., Boyd, J. M., and Chinnadurai, G. (1995). Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins. Oncogene 11: 2403-2409.
22. Marcellus, R. C., Teodoro, J. G., Charbonneau, R., Shore, G. C., and Branton, P. E. (1996). Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein. Cell Growth Differ. 7: 1643-1650.
23. Harada, J. N., and Berk, A. J. (1999). p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73: 5333-5344.
24. Hutton, F. G., Turnell, A. S., Gallimore, P. H., and Grand, R. J. (2000). Consequences of disruption of the interaction between p53 and the larger adenovirus early region 1B protein in adenovirus E1 transformed human cells. Oncogene 19: 452-462.
25. Babiss, L. E., Ginsberg, H. S., and Darnell, J. E., Jr. (1985). Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5: 2552-2558.
26. Williams, J., Karger, B. D., Ho, Y. S., Castaglia, T., Mann, T., and Flint, S. J. (1986). The adenovirus E1B 495R protein plays a role in regulating the transport and stability of the viral late messages. Cancer Cells 4: 275-284.
27. Pilder, S., Moore, M., Logan, J., and Shenk, T. (1986). The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell. Biol. 6: 470-476.
28. Goodrum, F. D., and Ornelles, D. A. (1997). The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71: 548-561.
29. Goodrum, F. D., and Ornelles, D. A. (1998). p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72: 9479-9490.
30. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. (1998). p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nat. Med. 4: 1068-1072.
31. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur Hausen, H. (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72: 9470-9478.
32. Turnell, A. S., Grand, R. J., and Gallimore, P. H. (1999). The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73: 2074-2083.
33. Fueyo, J., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
34. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59-74.
35. Jacobs, J. P. (1976). Updated results on the karyology of the WI-38, MRC-5 and MRC-9 cell strains. Dev. Biol. Stand. 37: 155-156.
36. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
37. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. (1991). The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88: 5523-5527.
38. Carroll, A. G., Voeller, H. J., Sugars, L., and Gelmann, E. P. (1993). p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23: 123-134.
39. Asai, A., et al. (1994). Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol. 19: 259-268.
40. Lehman, T. A., et al. (1991). p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51: 4090-4096.
41. Aagaard, L., Lukas, J., Bartkova, J., Kjerulff, A. A., Strauss, M., and Bartek, J. (1995). Aberrations of p16lnk4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer 61: 115-120.
42. Okamoto, A., Tsuruta, K., Isawa, T., Kamisawa, T., Tanaka, Y., and Onodera, T. (1994). Intraoperative radiation therapy for pancreatic carcinoma. The choice of treatment modality. Int. J. Pancreatol. 16: 157-164.
43. Jarrard, D. F., et al. (1997). Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90-96.
44. Poulos, N. E., Farmer, A. A., Chan, K. W., and Stanbridge, E. J. (1996). Design of a novel bicistronic expression vector with demonstration of a p16INK4-induced G(1)-S block(1). Cancer Res. 56: 1719-1723.
45. McLorie, W., McGlade, C. J., Takayesu, D., and Branton, P. E. (1991). Individual adenovirus E1B proteins induce transformation independently but by additive pathways. J. Gen. Virol. 72: 1467-1471.
46. Jones, N., and Shenk, T. (1979). An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 76: 3665-3669.
47. Wills, K. N., Huang, W. M., Harris, M. P., Machemer, T., Maneval, D. C., and Gregory, R. J. (1995). Gene therapy for hepatocellular carcinoma: Chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 2: 191-197.
48. Huyghe, B. G., et al. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6: 1403-1416.
49. Jelsma, T. N., et al. (1988). Use of deletion and point mutants spanning the coding region of the adenovirus 5 E1A gene to define a domain that is essential for transcriptional activation. Virology 163: 494-502.
50. Egan, C., Jelsma, T. N., Howe, J. A., Bayley, S. T., Ferguson, B., and Branton, P. E. (1988). Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol. Cell. Biol. 8: 3955-3959.
51. Bett, A. J., Krougliak, V., and Graham, F. L. (1995). DNA sequence of the deletion/insertion in early region 33 of Ad5 dl309. Virus Res. 39: 75-82.
52. Wang, H. G., et al. (1993). Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J. Virol. 67: 476488.
53. Dyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12: 2245-2262.
54. Trouche, D., and Kouzarides, T. (1996). E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP. Proc. Natl. Acad. Sci. USA 93: 1439-1442.
55. Jaffe, H. A., et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1: 372-378.
56. Li, Q., Kay, M. A., Finegold, M., Stratford-Perricaudet, L. D., and Woo, S. L. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4: 403-409.
57. Bayley, S. T., and Mymryk, J. S. (1994). Adenovirus E1A proteins and transformation. Int. J. Oncol. 5: 425-444.
58. Hay, J. G., Shapiro, N., Sauthoff, H., Heitner, S., Phupakdi, W., and Rom, W. N. (1999). Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 10: 579-590.
59. Ganly, I., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6: 798-806.
60. Grand, R. J., Parkhill, J., Szestak, T., Rookes, S. M., Roberts, S., and Gallimore, P. H. (1999). Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene 18: 955-965.